Myeloid-derived suppressor cells (MDSC) accumulate in patients and animals with cancer
where they mediate systemic immune suppression and obstruct immune-based cancer
therapies. We have previously demonstrated that inflammation, which frequently
accompanies tumor onset and progression, increases the rate of accumulation and the
suppressive potency of MDSC. To determine how inflammation enhances MDSC levels and
activity we used mass spectrometry to identify proteins produced by MDSC induced in highly …